LOXL1 Inhibitors
The chemical class of LOXL1 inhibitors comprises a diverse array of compounds that exert their inhibitory effects through intricate interactions with specific cellular signaling pathways. These pathways play crucial roles in regulating LOXL1 expression and enzymatic activity, ultimately influencing its impact on extracellular matrix remodeling processes. Nordihydroguaiaretic acid, for instance, targets the NF-κB signaling pathway, disrupting the activation of transcription factors involved in LOXL1 gene expression. Luteolin, on the other hand, acts as an indirect inhibitor by modulating the TGF-β signaling pathway. It interferes with Smad protein phosphorylation, hindering the transcriptional activation of LOXL1 and contributing to the downregulation of its expression. This theme continues with gallic acid, which targets the PI3K/Akt signaling pathway. By impeding Akt phosphorylation, gallic acid disrupts the downstream activation of transcription factors responsible for LOXL1 gene expression.
Resveratrol, quercetin, baicalein, and genistein showcase the versatility of indirect inhibition, each targeting distinct pathways such as JAK/STAT, MAPK/ERK, Wnt/β-catenin, and Notch, respectively. These compounds interfere with critical steps in these signaling cascades, resulting in diminished LOXL1 activity and expression. The chemical class also includes compounds like ursolic acid, ellagic acid, piceatannol, curcumin, and chrysin, which influence Hedgehog, Hippo, mTOR, Nrf2, and AMPK signaling pathways, respectively. These interactions showcase the intricate web of cellular processes that can be modulated to regulate LOXL1 activity indirectly. In summary, the chemical class of LOXL1 inhibitors encompasses a spectrum of compounds, each with a unique mechanism of action targeting specific signaling pathways. This targeted approach provides a nuanced understanding of how these inhibitors interfere with cellular processes to ultimately regulate LOXL1 expression and function in the context of extracellular matrix remodeling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NDGA (Nordihydroguaiaretic acid) | 500-38-9 | sc-200487 sc-200487A sc-200487B | 1 g 5 g 25 g | $109.00 $384.00 $2190.00 | 3 | |
Nordihydroguaiaretic acid is a natural phenolic compound that inhibits LOXL1 indirectly by targeting the NF-κB signaling pathway. It disrupts the activation of NF-κB, which is known to regulate LOXL1 expression. This interference results in a downregulation of LOXL1 levels, impacting its enzymatic activity and ultimately inhibiting its function in extracellular matrix remodeling. | ||||||
Luteolin | 491-70-3 | sc-203119 sc-203119A sc-203119B sc-203119C sc-203119D | 5 mg 50 mg 500 mg 5 g 500 g | $27.00 $51.00 $101.00 $153.00 $1925.00 | 40 | |
Luteolin acts as an indirect LOXL1 inhibitor by modulating the TGF-β signaling pathway. It hinders the phosphorylation of Smad proteins in the TGF-β pathway, subsequently suppressing the transcriptional activation of LOXL1. This disruption in the signaling cascade leads to reduced LOXL1 expression and enzymatic activity, contributing to the inhibition of LOXL1-mediated processes in the extracellular matrix. | ||||||
Gallic acid | 149-91-7 | sc-205704 sc-205704A sc-205704B | 10 g 100 g 500 g | $56.00 $87.00 $245.00 | 14 | |
Gallic acid functions as a LOXL1 inhibitor by targeting the PI3K/Akt signaling pathway. It interferes with Akt phosphorylation, impeding the downstream activation of transcription factors involved in LOXL1 gene expression. Consequently, gallic acid-induced inhibition disrupts the normal cellular processes mediated by LOXL1, offering a potential avenue for regulating LOXL1 activity in extracellular matrix dynamics. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol serves as an indirect inhibitor of LOXL1 through its impact on the JAK/STAT signaling pathway. By inhibiting JAK activation, resveratrol disrupts the downstream STAT-mediated transcription of LOXL1, leading to reduced expression and activity of LOXL1 in extracellular matrix remodeling processes. This modulation highlights a potential avenue for controlling LOXL1 function through interference with the JAK/STAT pathway. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin acts as an indirect LOXL1 inhibitor by targeting the MAPK/ERK signaling pathway. It hinders the phosphorylation cascade in this pathway, ultimately downregulating the expression of LOXL1. The disruption in MAPK/ERK signaling induced by quercetin leads to diminished LOXL1 activity, providing a mechanism for regulating LOXL1-mediated processes in the extracellular matrix. | ||||||
Baicalein | 491-67-8 | sc-200494 sc-200494A sc-200494B sc-200494C | 10 mg 100 mg 500 mg 1 g | $32.00 $42.00 $162.00 $292.00 | 12 | |
Baicalein functions as an indirect LOXL1 inhibitor by modulating the Wnt/β-catenin signaling pathway. It interferes with β-catenin nuclear translocation, suppressing the downstream transcriptional activation of LOXL1. This disruption results in decreased LOXL1 expression and enzymatic activity, offering a potential strategy for regulating LOXL1-mediated processes in the extracellular matrix. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein serves as an indirect LOXL1 inhibitor by targeting the Notch signaling pathway. It inhibits Notch receptor cleavage and activation, leading to downstream effects that include the suppression of LOXL1 gene expression. The interference with Notch signaling by genistein offers a potential avenue for controlling LOXL1 activity and its impact on extracellular matrix remodeling processes. | ||||||
Ursolic Acid | 77-52-1 | sc-200383 sc-200383A | 50 mg 250 mg | $56.00 $180.00 | 8 | |
Ursolic acid acts as an indirect LOXL1 inhibitor by influencing the Hedgehog signaling pathway. It disrupts the Hedgehog signaling cascade, leading to reduced expression of LOXL1. This interference with Hedgehog signaling provides a potential mechanism for controlling LOXL1 activity and its role in extracellular matrix remodeling processes. | ||||||
Ellagic Acid, Dihydrate | 476-66-4 | sc-202598 sc-202598A sc-202598B sc-202598C | 500 mg 5 g 25 g 100 g | $58.00 $95.00 $245.00 $727.00 | 8 | |
Ellagic acid functions as an indirect LOXL1 inhibitor by targeting the Hippo signaling pathway. It modulates Hippo signaling, leading to downstream effects that include the suppression of LOXL1 gene expression. This interference with Hippo signaling by ellagic acid offers a potential avenue for regulating LOXL1 activity and its impact on extracellular matrix remodeling processes. | ||||||
Piceatannol | 10083-24-6 | sc-200610 sc-200610A sc-200610B | 1 mg 5 mg 25 mg | $51.00 $71.00 $199.00 | 11 | |
Piceatannol serves as an indirect LOXL1 inhibitor by influencing the mTOR signaling pathway. It inhibits mTOR activation, leading to downstream effects that include the suppression of LOXL1 gene expression. The interference with mTOR signaling by piceatannol offers a potential mechanism for controlling LOXL1 activity and its role in extracellular matrix remodeling processes. | ||||||